HARBIN, China, May 21 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (''Renhuang’’ or ''the Company’’), a leading pharmaceutical company in the People’s Republic of China (''PRC’’), today announced its successful participation in the Heilongjiang Biology Industry Development Fair on May 9th, 2008.
Heilongjiang Biology Industry Development Fair is intended to enhance the cooperation between the enterprises and research and development institutions in Heilongjiang Province. There were more than 600 projects in fields as diverse as biomedicine, biological agriculture, biological energy, biological environmental protection and other bio-related areas presented in the fair. The fair has attracted science and technology institutions, universities and colleges with the bio-related research, enterprises, researchers and industry experts from around the province. About 1,000 professionals in the biology industry attended the fair.
Renhuang presented its leading branded drug, Acanthopanax (Siberian Ginseng), and the scientific research on it. Acanthopanax, extracted from natural plants for the treatment of sleep disorders and depression, was highly popular among the attendees. Especially, the Minister of Heilongjiang Province highly praised Acanthopanax for its effective treatment and believed it would have a promising future in the market. The Company signed collaboration contracts with Heilongjiang Chinese Medicine University and Northwest Forestry University at the event.
''We intend to continue our strategy of increasing our presence at fairs and exhibitions to promote our research and development capability. Additionally, the cooperation between the Renhuang and research and development institutions not only helps the R&D turn laboratory achievements into commercial production but also brings Renhuang infinite innovation resources,’' said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals, Inc.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company’s GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceutical products using its extensive distribution channels and third party distributors throughout China. The Company’s distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Ms. Shuang Tan, IR Contact of Renhuang Pharmaceuticals, Inc.,
+86-451-5392-5461, or ir@renhuang.com; Mr. Crocker Coulson, President of
CCG, +1-646-213-1915 (New York), crocker.coulson@ccgir.com
Web site: http://www.ccgelite.com/
http://www.renhuang.com/
